The distribution of pharmacogenetic variation observed in this diverse cohort of Canadian pediatric IBD patients supports the utility of both TPMT and NUDT15 genotyping to provide the best care possible for patients in advance of thiopurine treatment. Here, NUDT15 is linked to inflammatory bowel disease.